欧康维视生物-B二零二四年年报

(Incorporated in the Cayman Islands with limited liability)(於開曼群島註冊成立的有限公司)Stock code股份代號: 1477 Virtus et LumenVirtus et Lumen勇 氣 和 光 明勇 氣 和 光 明 目錄 2468223047788586878890155 ʮ̡༟ࣘ 授權代表 董事會 執行董事Ye LIU Ye LIU 註冊辦事處 非執行董事 Vistra (Cayman) LimitedP.O. Box 31119 Grand PavilionHibiscus Way802 West Bay RoadGrand Cayman KY1-1205Cayman Islands Lian Yong CHENWei LI2025116202410212025116 公司總部及中國主要營業地點 1858 審核委員會 香港主要營業地點 894417 薪酬委員會 開曼群島主要股份過戶登記處 提名委員會 Vistra (Cayman) LimitedP.O. Box 31119 Grand PavilionHibiscus Way, 802 West Bay RoadGrand Cayman, KY1-1205Cayman Islands Lian Yong CHEN 聯席公司秘書 HKACGACG 香港證券登記處 1831717121716 香港法律顧問 1526 核數師 •8835 股份代號 1477 公司網站www.ocumension.com ᗘߧࢩ˴ 2024 2024®(OT-1001)OT-702OT-502NDAOT-301IIIOT-202 2024417.369.4%®(OT-401) 2024CDMO 202410Alcon87AlconAlcon 2025 Lian Yong CHEN ࠅৌਕ฿ (1)(a)(i)(ii)(iii)(b)EyePointAlimera ၍ଣᄴীሞʿʱؓ 3421III®0.18®0.24%20241231 業務回顧 整體財務表現 417.369.4%53.9%®®®®Alcon113.9®0.24%20249183.624.5% 研發表現 ®0.24%FDA20252®OT-702®IIIOT-702(BLA)20247CDEOT-502IIINDA20249OT-202II IIIIII ၍ଣᄴীሞʿʱؓ 主要候選藥物的研發進展 •OT-101（0.01%硫酸阿托品滴眼液） OT-101III OT-1012026III •OT-202（酪氨酸激酶抑制劑） 20243OT-202II56 2025OT-202III •OT-702（博優景®，阿柏西普眼內注射溶液） 20244VEGFOT-702IIIIII4812162024(BCVA)(ETDRS)OT-702 20247OT-702(BLA)CDEOT-7022025 •OT-502（DEXYCU®，地塞米松植入劑） 20244OT-502IIIOT-502III9%OT-502III8ACC0OT-502NDA20249 OT-502 •OT-301 (NCX 470) 202412OT-301(NCX 470)(NO)IIIDenali140DenaliIIIOT-3010.1%0.005%(IOP) OT-301III 商業化表現 ®®®®417.369.4%20,4662,765270 20248AlconAlconAlcon87Alcon(a)®®II®®®®(b)®(c)Alcon20241016AlconPharma139,159,664AlconAlcon16.99%Alcon PharmaAlconAlcon ၍ଣᄴীሞʿʱؓ 生產表現 11®3 未來發展與展望 2024®2025 •加速新產品研發與商業化 NDA •優化生產與供應鏈管理 2025 •推廣核心產品優施瑩® ®2025 •加強其他藥品的營銷與推廣 ®®®®® •深化企業文化建設 2025 •拓展國際視野 •持續創新與技術領先 •擴大線上OTC渠道 OTCOTC ၍ଣᄴীሞʿʱؓ 財務回顧 概覽 20231231246.469.4%20241231417.3202410AlconAlcon 20241231183.620231231243.224.5% 收益 20231231246.420241231417.3(a)87.8%(i)202312®(ii)®®(iii)AlconAlcon(b)CDMO9.8CDMO(c)4.1®® CDMO 銷售成本 20231231102.020241231192.2(i)(ii)®® ၍ଣᄴীሞʿʱؓ 毛利 20231231144.455.9%20241231225.1 其他收入 (i)(ii)Alcon(iii)2024123146.72023123123.223.5AlconAlcon 其他收益及虧損 202412311.4202312315.4(i)202420233.2(ii)20240.520231.2(iii)Nicox0.6202412310.8 銷售及營銷開支 (i)(ii)(iii)20241231227.720231231226.31.4 研發開支 113.920231231123.87.9%(i)II(ii) 行政開支 (i)(ii)(iii)(iv) 20241231189.220231231196.16.920242023 所得稅開支 202412311.0202312310.3 年內虧損 20241231268.320231231379.8111.580.723.5 ၍ଣᄴীሞʿʱؓ 非國際財務報告準則計量指標 貿易應收款項 3090 20241231 貿易應付款項 營運資金及資金來源 (i)(ii)(iii)(i)®®®®®®(ii)(iii)CDMO20241231729.220231231842.8 借款 2024123116.520231231120.00.35%20233.0%3.1% 資本承擔 202412315.0202312316.4 或然負債 2024123120231231 資產質押 20241231202312314.3 ၍ଣᄴীሞʿʱؓ 資產負債比率 100%20241231 重大投資、收購及出售 1,910,500EyePoint37,159,000290,583,000EyePoint2024117100,221EyePointEyePoint0.21% 20241231EyePoint5.420231231329.1202412310.14% AlconAlcon20248122024930AlconAlconPharma139,159,664Alcon16.99% 20241231 重大投資或資本資產的未來計劃 外匯 僱員及薪酬 202412314892023123144420241231318.220231231314.620241231 ESOPRSU202120212024 ໨ԫʿ৷ॴ၍ଣᄴ฿ᚎ 董事 執行董事 •YeLIU5320188120181123Liu Liu24201410201872009220149LiuLiu2021120246EyePoint Liu2003819937 •522018932020424202061 242006720188 200231999319967 非執行董事 •LianYong CHEN622018523201852320204282021720 Chen286Dimensions Capital2012 20198201912Chen2487968620195Chen111YI201512022316255220181029202179261620141220215246037182008520143ChenFILCapital Management (Hong Kong) Limited Chen199161991819921219847 •412019618 15GeneralAtlantic LLC2007122011120113Boyu Capital Group Management Ltd.20164201732019520231201610202136078201942021360308720192202112699620205202112212620165226920182Viela Bio, Inc.VIE20213 20065 ໨ԫʿ৷ॴ၍ଣᄴ฿ᚎ •442025120182202012 201792016120178201392015126002672010112012126016072607 201982022112022112487 200372004920114 獨立非執行董事 •702020623 20002017201020122011201420072012 1406250000060966151526161105104C87001 19757 ໨ԫʿ৷ॴ၍ଣᄴ฿ᚎ •702020623 201652019122009620151 19897198212 •4923Thea2 Milk CompanyLimitedATMA2M20121020192TMOAPAC20113201210APAC2008420113TOM201953666 19982010BiMBA 高級管理層 •YeLIU53201881 •52202061 41202111 20189202112015420188201010201532009620109 2009520066 •392023112 202011202312018120201120162201812013920161Sullivan & Cromwell LLP 202111200912 ໨ԫʿ৷ॴ၍ଣᄴ฿ᚎ •4720231GMP2025220198202312017320198GMPGMP20007201736016072607QA 20007 •422024120235202312202210202352019420221020159201932013820159 20056201062010720127 •392023930 •302023930202171 20209202166562017420209600332874 2016112023320237 董事資料變動 2023 1.YeLIU2024620EyePoint 13.51B(1) Άุ၍طజѓ 企業管治常規 20241231(5) 公司文化 20207SloganVirtuset Lumen1 821 董事會 (1)職責 (2)董事及高級管理層的責任保險及彌償保證 (3)董事會組成 執行董事 Ye LIU 非執行董事 Lian Yong CHENWei LI2025116202410212025116 獨立非執行董事 3.10(1)3.10(2)3.10A3.10(2) Άุ၍طజѓ (4)董事會成員多元化政策 13.92 4170 2228 (5)可計量目標 2024102113.92202511613.92 2024123148947.4% (6)董事會獨立性 37.5% Άุ၍طజѓ (7)獨立非